» Articles » PMID: 10626893

Synergistic Roles for Pim-1 and C-Myc in STAT3-mediated Cell Cycle Progression and Antiapoptosis

Overview
Journal Immunity
Publisher Cell Press
Date 2000 Jan 8
PMID 10626893
Citations 135
Authors
Affiliations
Soon will be listed here.
Abstract

The activation of STAT3 by the cytokine receptor gp130 is required for both the G1 to S cell cycle transition and antiapoptosis. We found that Pim-1 and Pim-2 are targets for the gp130-mediated STAT3 signal. Expression of a kinase-defective Pim-1 mutant attenuated gp130-mediated cell proliferation. Constitutive expression of Pim-1 together with c-myc, another STAT3 target, fully compensated for loss of the STAT3-mediated cell cycle progression, antiapoptosis, and bcl-2 expression. We also identified valosine-containing protein (VCP) as a target gene for the Pim-1-mediated signal. Expression of a mutant VCP led cells to undergo apoptosis. These results indicate that Pim-family proteins play crucial roles in gp130-mediated cell proliferation and explain the synergy between Pim and c-Myc proteins in cell proliferation and lymphomagenesis.

Citing Articles

PIM1 kinase and its diverse substrate in solid tumors.

Choudhury R, Bahadi C, Ray I, Dash P, Pattanaik I, Mishra S Cell Commun Signal. 2024; 22(1):529.

PMID: 39487435 PMC: 11531143. DOI: 10.1186/s12964-024-01898-y.


PIM Kinase Inhibitors as Novel Promising Therapeutic Scaffolds in Cancer Therapy.

Karati D, Saha A, Roy S, Mukherjee S Curr Top Med Chem. 2024; 24(28):2489-2508.

PMID: 39297470 DOI: 10.2174/0115680266321659240906114742.


Interleukin 6 and cancer resistance in glioblastoma multiforme.

Detchou D, Barrie U Neurosurg Rev. 2024; 47(1):541.

PMID: 39231832 DOI: 10.1007/s10143-024-02783-5.


Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease.

Meur S, Mukherjee S, Roy S, Karati D Mol Neurobiol. 2024; 61(12):10941-10955.

PMID: 38816674 DOI: 10.1007/s12035-024-04257-7.


Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery.

Hu Y, Dong Z, Liu K J Exp Clin Cancer Res. 2024; 43(1):23.

PMID: 38245798 PMC: 10799433. DOI: 10.1186/s13046-024-02949-5.